Free Trial
NASDAQ:IXHL

Incannex Healthcare Q2 2025 Earnings Report

Incannex Healthcare logo
$0.59 +0.03 (+5.17%)
Closing price 04/23/2025 03:50 PM Eastern
Extended Trading
$0.56 -0.03 (-5.08%)
As of 08:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Incannex Healthcare EPS Results

Actual EPS
-$0.33
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Incannex Healthcare Revenue Results

Actual Revenue
$10.00 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Incannex Healthcare Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Friday, February 14, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Incannex Healthcare's Q3 2025 earnings is scheduled for Wednesday, May 21, 2025, with a conference call scheduled on Friday, May 16, 2025 at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Incannex Healthcare Earnings Headlines

The Man I Turn to In Times Like This
A storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when publisher Brett Aitken turns to Whitney Tilson—a man CNBC once dubbed “The Prophet.” Tilson just released a new prediction that runs counter to what mainstream finance is telling you.
See More Incannex Healthcare Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Incannex Healthcare? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Incannex Healthcare and other key companies, straight to your email.

About Incannex Healthcare

Incannex Healthcare (NASDAQ:IXHL), a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

View Incannex Healthcare Profile

More Earnings Resources from MarketBeat